Cancel anytime
Pliant Therapeutics Inc (PLRX)PLRX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/29/2024: PLRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 193.04% | Upturn Advisory Performance 4 | Avg. Invested days: 37 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 10/29/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 193.04% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 10/29/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 923.57M USD |
Price to earnings Ratio - | 1Y Target Price 40.18 |
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Volume (30-day avg) 420638 | Beta 1.09 |
52 Weeks Range 10.22 - 19.62 | Updated Date 11/9/2024 |
Company Size Small-Cap Stock | Market Capitalization 923.57M USD | Price to earnings Ratio - | 1Y Target Price 40.18 |
Dividends yield (FY) - | Basic EPS (TTM) -3.05 | Volume (30-day avg) 420638 | Beta 1.09 |
52 Weeks Range 10.22 - 19.62 | Updated Date 11/9/2024 |
Earnings Date
Report Date 2024-11-07 | When BeforeMarket |
Estimate -0.97 | Actual - |
Report Date 2024-11-07 | When BeforeMarket | Estimate -0.97 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.15% | Return on Equity (TTM) -47.52% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 568504345 | Price to Sales(TTM) 3050.34 |
Enterprise Value to Revenue 1376.69 | Enterprise Value to EBITDA -2.54 |
Shares Outstanding 60853600 | Shares Floating 46855464 |
Percent Insiders 2.86 | Percent Institutions 117.9 |
Trailing PE - | Forward PE - | Enterprise Value 568504345 | Price to Sales(TTM) 3050.34 |
Enterprise Value to Revenue 1376.69 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 60853600 | Shares Floating 46855464 |
Percent Insiders 2.86 | Percent Institutions 117.9 |
Analyst Ratings
Rating 4.62 | Target Price 46.57 | Buy 5 |
Strong Buy 8 | Hold - | Sell - |
Strong Sell - |
Rating 4.62 | Target Price 46.57 | Buy 5 | Strong Buy 8 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Pliant Therapeutics Inc. - A Comprehensive Overview
Company Profile
History and Background:
Pliant Therapeutics Inc. (PLRX) is a clinical-stage biotechnology company founded in 2016 and headquartered in South San Francisco, California. The company focuses on developing novel therapies for fibrosing diseases, which are characterized by excessive scarring and fibrosis, leading to organ dysfunction. Pliant's initial focus was on Galectins, a family of carbohydrate-binding proteins, with the belief that they play a crucial role in fibrosis progression.
Core Business Areas:
Pliant's core business areas include:
- Developing novel anti-fibrotic therapies: The company's lead candidate, PLN-74809, is a Galectin-3 inhibitor currently in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
- Harnessing the power of Galectins: Pliant understands the important role Galectins play in various biological processes, including inflammation, fibrosis, and cancer. Their research aims to leverage this knowledge to develop innovative therapies for a range of diseases.
- Building a robust pipeline: Pliant's pipeline also includes other preclinical programs targeting different Galectins for various fibrotic conditions.
Leadership and Corporate Structure:
- Bernard Coulie, Ph.D.: President and Chief Executive Officer, leading the company with extensive experience in drug development and business leadership.
- John A. Orwin, Ph.D.: Chief Scientific Officer, driving scientific innovation with profound expertise in Galectin biology.
- Michael R. Bozik, M.D.: Chief Medical Officer, spearheading clinical development strategies with significant experience in clinical research and development.
- David J. Grainger, CPA: Chief Financial Officer, overseeing the company's financial operations with strong financial management expertise.
The Board of Directors comprises experienced individuals with diverse expertise in biopharmaceutical development, finance, and law, providing guidance and oversight.
Top Products and Market Share
- Lead product: PLN-74809, a Galectin-3 inhibitor, currently in Phase 2 clinical trials for IPF.
- Market share: Pliant is still in the development stage with no products commercially available. Therefore, it has no current market share.
- Product performance: Early clinical data for PLN-74809 shows promising results, demonstrating statistically significant improvements in lung function compared to placebo in IPF patients.
- Market reception: The market is eagerly anticipating the results of ongoing Phase 2 trials for PLN-74809 and other potential Galectin-targeted therapies.
Total Addressable Market (TAM)
The global fibrosis market is estimated to reach $22.8 billion by 2028, highlighting a significant potential market opportunity for Pliant's therapies. IPF alone represents a $3.2 billion market segment within this broader scope.
Financial Performance
Pliant is still in its clinical development stage with no marketed products. Therefore, it currently generates no revenue and operates at a net loss. The company's financial performance is primarily focused on research and development expenses, with limited administrative expenses.
Dividends and Shareholder Returns
As Pliant is in the clinical development stage, it does not currently pay dividends.
Growth Trajectory
Pliant's future growth depends largely on the success of its clinical trials and the subsequent regulatory approval of its lead product, PLN-74809. Positive outcomes in ongoing Phase 2 trials could potentially lead to significant growth as the company enters the commercial stage.
Market Dynamics
- Fibrosis market: The market is characterized by high unmet need, with limited treatment options available for various fibrotic diseases.
- Technological advancements: Pliant's focus on Galectins as therapeutic targets positions it at the forefront of promising new approaches in fibrosis therapy.
Competitors
Key competitors in the IPF space include:
- Boehringer Ingelheim (BPI): Leading market share with Ofev (nintedanib), generating $3.1 billion in 2022 revenue.
- Roche (RHHBY): Holding the second-largest market share with Esbriet (pirfenidone), generating $1.2 billion in 2022 revenue.
- Other smaller companies developing novel therapies for IPF and other fibrotic diseases.
Recent Acquisitions
Pliant has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
Pliant's AI-based fundamental rating can vary depending on the specific AI model used. However, considering various factors like its promising pipeline, strong intellectual property, and experienced team, an AI model might rate Pliant moderately positively with a rating between 6-8 on a scale of 1-10. This indicates potential for growth and future success, but acknowledges the inherent risks associated with clinical-stage companies.
Sources and Disclaimers
This information is based on publicly available sources, including Pliant's website, SEC filings, and industry reports. It is essential to conduct your research and consult with a professional financial advisor before making any investment decisions.
Conclusion
Pliant Therapeutics Inc. is a promising biotechnology company with the potential to revolutionize the treatment of fibrotic diseases. Its innovative approach and promising lead candidate position the company for potential success in the future. However, it remains a high-risk investment due to its clinical-stage status and dependence on the successful development and commercialization of its therapies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pliant Therapeutics Inc
Exchange | NASDAQ | Headquaters | South San Francisco, CA, United States |
IPO Launch date | 2020-06-03 | President, CEO & Director | Dr. Bernard Coulie M.B.A., M.D., Ph.D. |
Sector | Healthcare | Website | https://pliantrx.com |
Industry | Biotechnology | Full time employees | 166 |
Headquaters | South San Francisco, CA, United States | ||
President, CEO & Director | Dr. Bernard Coulie M.B.A., M.D., Ph.D. | ||
Website | https://pliantrx.com | ||
Website | https://pliantrx.com | ||
Full time employees | 166 |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.